Genticel

Genticel to continue per protocol its phase II study with ProCervix after review by DSMB

Thursday, January 29, 2015 10:54 AM

Genticel, a French biotechnology company and developer of therapeutic vaccines, has announced that the Data and Safety Monitoring Board (DSMB), an independent committee of experts which monitors safety data every six months during a study, met as scheduled on Jan. 22. It recommended the RHEIA-VAC study proceed without any modifications. The DSMB already had made the same recommendation during the first review on July 1, 2014.

More... »


Genticel completes recruitment for phase Ib HPV vaccine trial

Wednesday, March 7, 2012 06:15 AM

Genticel, a biopharmaceutical company based in Toulouse and Paris, France, has completed the recruitment of all patients participating in its phase Ib clinical trial evaluating a lyophilized formulation of ProCervix, its candidate therapeutic HPV vaccine, on adult women already infected with human papillomavirus (HPV) genotypes 16 or 18.

More... »


Genticel completes patient recruitment for ProCervix trial

Wednesday, October 19, 2011 11:31 AM

Genticel has completed the recruitment of all patients participating in its phase one clinical trial with a liquid formulation of ProCervix, its candidate therapeutic HPV vaccine designed for adult women already infected with human papillomavirus (HPV) genotype 16 or 18.

More... »

Genticel names Dr. Hoch to supervisory board

Wednesday, July 6, 2011 10:21 AM

Genticel, a clinical biopharmaceutical company developing vaccines for human papillomavirus (HPV), has appointed Dr. Didier Hoch to the company’s supervisory board.

More... »


CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs